Huntington's disease: Objective assessment of posture-A link between motor and functional deficits

Movement Disorders

Volumn 27, Issue 4, 2012, Pages 555-559

  Reilmann, Ralf ^a   Rumpf, Silke ^a   Beckmann, Heike ^a   Koch, Raphael ^a   Ringelstein, Erich B ^a   Lange, Herwig W ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Balance; Basal ganglia; Huntington's disease posture; Motor control; Outcome research

Indexed keywords

ADULT; AGED; ARTICLE; BALANCE DISORDER; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE SEVERITY; FEMALE; FUNCTIONAL DISEASE; GENOTYPE; HUMAN; HUNTINGTON CHOREA; MALE; MOTOR DYSFUNCTION; PHENOTYPE; PRIORITY JOURNAL; STABILOGRAPHY;

ADULT; AGED; FEMALE; HUMANS; HUNTINGTON DISEASE; MALE; MIDDLE AGED; MOVEMENT; POSTURE; SENSATION DISORDERS; STATISTICS AS TOPIC; STATISTICS, NONPARAMETRIC; TILT-TABLE TEST; YOUNG ADULT;

EID: 84859422752     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.24908     Document Type: Article

References (19)

1. Walker FO. Huntington's disease. Lancet. 2007;20; 369: 218-228.
2. Reilmann R, Bohlen S, Klopstock T, et al. Grasping premanifest Huntington's disease - shaping new endpoints for new trials. Mov Disord. 2010; 25: 2858-2862.
3. Bechtel N, Scahill RI, Rosas HD, et al. Tapping linked to function and structure in premanifest and symptomatic Huntington disease. Neurology. 2010; 75: 2150-2160.
4. Tian J, Herdman SJ, Zee DS, et al. Postural stability in patients with Huntington's disease. Neurology. 1992; 42: 1232-1238.
5. Rao AK, Quinn L, Marder KS. Reliability of spatiotemporal gait outcome measures in Huntington's disease. Mov Disord. 2005; 20: 1033-1037.
6. Grimbergen YA, Knol MJ, Bloem BR, et al. Falls and gait disturbances in Huntington's disease. Mov Disord. 2008; 23: 970-976.
7. Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord. 1996; 11: 136-142.
8. Landwehrmeyer GB, Dubois B, de Yebenes JG, et al. Riluzole in Huntington's disease: a 3-year, randomized controlled study. Ann Neurol. 2007; 62: 262-272.
9. Huntington Study Group. Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study. Arch Neurol. 2008; 65: 1582-1589.
10. Penney JBJ, Vonsattel JP, MacDonald ME, et al. CAG repeat number governs the development rate of pathology in Huntington's disease. Ann Neurol. 1997; 41: 689-692.
11. Marder K, Zhao H, Myers RH, et al. Rate of functional decline in Huntington's disease. Huntington Study Group. Neurology. 2000; 54: 452-458.
12. Huntingtom Study Group. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology. 2001; 57: 397-404.
13. Wexler NS, Lorimer J, Porter J, et al. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. Proc Natl Acad Sci U S A. 2004; 101: 3498-3503.
14. Reilmann R, Kirsten F, Quinn L, et al. Objective assessment of progression in Huntington's disease: a 3-year follow-up study. Neurology. 2001; 57: 920-924.
15. Michell AW, Goodman, AO, Silva, AH, et al. Hand tapping: a simple, reproducible, objective marker of motor dysfunction in Huntington's disease. J Neurol. 2008; 2551145-1152.
16. Tabrizi SJ, Scahill RI, Durr A, et al. Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol. 2011; 10: 31-42.
17. Paulsen JS, Hayden M, Stout JC, et al. Preparing for preventive clinical trials: the Predict-HD study. Arch Neurol. 2006; 63: 883-890.
18. Tabrizi SJ, Langbehn DR, Leavitt BR, et al. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol. 2009; 8: 791-801.
19. Weir DW, Sturrock A, Leavitt BR. Development of biomarkers for Huntington's disease. Lancet Neurol. 2011; 10: 573-590.